Brain Scientific (BRSF) Developing State-of-the-Art AI Diagnostic Analytics
- BRSF working to improve diagnostics by leveraging AI and machine learning
- Cloud-based infrastructure, AI-assisted diagnostic analysis is in development phase
- Brain Scientific creating long-term monitoring capabilities that leads to collection of essential biomarkers
Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly.
But BRSF isn’t stopping there.
The company’s goal is to further improve diagnostics by leveraging artificial intelligence (“AI”) and machine learning processes to analyze a database of brain readings to improve diagnosis and treatment of neurological conditions.
The company is using in-house development in order to provide diagnostic interpretation assistance for health-care providers. Currently, a secure cloud-based infrastructure and AI-assisted diagnostic analysis are in the development phase.
BRSF’s remote diagnostic devices that are already in active use will be used to acquire large datasets of neurological information that will be uploaded to the company’s secure cloud technology. These neural networks of data will be used to identify patterns and biomarkers for neurological disease in the near future. Eventually, this data will be integrated with external graph datasets that contain neurological clinical and research data. When that happens, the neural networks will comb the data to detect patterns. Over time the AI will be able to make predictions that will aid neurologists and increase access to complex neuro-diagnostic expertise (https://nnw.fm/XyZPn).
As more clinical trials and studies are done on neurological conditions, additional data is acquired. On the Neuroscience Information Framework (“NIF”), there are currently over 4,000 databases of neurological information (https://nnw.fm/VPjKN). No single neurologist can attempt to evaluate that much data to discover the best treatment for the one patient under their care.
But a computer can. By creating a secure cloud of BRSF’s data that can be integrated with external datasets and using AI with machine learning to filter through the data, neurologists will be able to locate the information needed to best help their patients. The implications of this technology is huge.
An article in Forbes states that “Biomarkers of Longevity integrated with AI and machine learning techniques have the potential to help prevent age-related diseases and extend health span,” reported a “Forbes” artice (https://nnw.fm/FVabr). “Advances in the development of biomarkers will allow doctors to assess health, quantify the effect of interventions, and produce personalized medical reports.”
Big data plus AI will make neurological care accessible in a way it has not yet been, and BRSF committed to help pave the way.
To learn more about this company, visit www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- BRSF working to improve diagnostics by leveraging AI and machine learning
- Cloud-based infrastructure, AI-assisted diagnostic analysis is in development phase
- Brain Scientific creating long-term monitoring capabilities that leads to collection of essential biomarkers
Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly.
But BRSF isn’t stopping there.
The company’s goal is to further improve diagnostics by leveraging artificial intelligence (“AI”) and machine learning processes to analyze a database of brain readings to improve diagnosis and treatment of neurological conditions.
The company is using in-house development in order to provide diagnostic interpretation assistance for health-care providers. Currently, a secure cloud-based infrastructure and AI-assisted diagnostic analysis are in the development phase.
BRSF’s remote diagnostic devices that are already in active use will be used to acquire large datasets of neurological information that will be uploaded to the company’s secure cloud technology. These neural networks of data will be used to identify patterns and biomarkers for neurological disease in the near future. Eventually, this data will be integrated with external graph datasets that contain neurological clinical and research data. When that happens, the neural networks will comb the data to detect patterns. Over time the AI will be able to make predictions that will aid neurologists and increase access to complex neuro-diagnostic expertise (https://nnw.fm/XyZPn).
As more clinical trials and studies are done on neurological conditions, additional data is acquired. On the Neuroscience Information Framework (“NIF”), there are currently over 4,000 databases of neurological information (https://nnw.fm/VPjKN). No single neurologist can attempt to evaluate that much data to discover the best treatment for the one patient under their care.
But a computer can. By creating a secure cloud of BRSF’s data that can be integrated with external datasets and using AI with machine learning to filter through the data, neurologists will be able to locate the information needed to best help their patients. The implications of this technology is huge.
An article in Forbes states that “Biomarkers of Longevity integrated with AI and machine learning techniques have the potential to help prevent age-related diseases and extend health span,” reported a “Forbes” artice (https://nnw.fm/FVabr). “Advances in the development of biomarkers will allow doctors to assess health, quantify the effect of interventions, and produce personalized medical reports.”
Big data plus AI will make neurological care accessible in a way it has not yet been, and BRSF committed to help pave the way.
To learn more about this company, visit www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
